Indian Tobacco Company Reports Strong Q2 2022 Performance

Aug.07.2022
Indian Tobacco Company Reports Strong Q2 2022 Performance
Indian Tobacco Company (ITC) reported strong Q2 performance with revenue and earnings growing 29% and 30.1% respectively.

According to a report from ITC (formerly known as the Indian Tobacco Company Limited, now the Indian Tobacco Company), their cigarette business achieved strong performance in the second quarter of 2022, with segment revenue and segment performance increasing by 29% and 30.1%, respectively, compared to the same period in the previous year.


Photo courtesy of Wirestock.


The Indian Tobacco Company released a statement declaring their commitment to combatting illegal trade. They plan to strengthen their market position through innovation, market segmentation, premiumization, improving product availability, and strict enforcement.


The Indian Tobacco Company has expressed encouragement towards the stable tobacco tax environment and enforcement actions taken by Indian authorities to eliminate illegal trade.


The Indian Tobacco Company stated in a press release that "as demonstrated in the past, stable cigarette taxes, supported by deterrent law enforcement actions, enable the legal cigarette industry to recover trade volumes from illegal trade, generating domestic demand for Indian tobacco, while also alleviating fiscal revenue losses.


The Indian Tobacco Company has stated that it continues to work with government agencies to develop a fair, non-discriminatory, practical, and evidence-based regulatory and taxation policy framework that balances economic benefits and tobacco control objectives. This takes into account India's unique patterns of tobacco consumption, with only a small portion of combustible tobacco production being used to manufacture cigarettes in Indian factories.


Statement:


This article is compiled from third-party information and is intended only for communication and learning within the industry.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truth or accuracy of the content. The translation of this article is only for industry communication and research purposes.


Due to limited translation abilities, the translated article may not fully reflect the original text. Please refer to the original version for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thailand’s Disease Control Department has warned that nicotine pouches (“Snus”) are classified as tobacco products and must comply with the Tobacco Products Control Act B.E. 2560 (2017). Officials said they have received complaints about sales and promotional activities, and stressed that these products must not be displayed or promoted at points of sale.
Feb.02 by 2FIRSTS.ai
Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia’s government commission on legislative activity has approved second-reading amendments to a bill on licensing trade in tobacco and nicotine-containing products that would allow Russian regions to introduce experimental bans on vape sales.
Mar.31 by 2FIRSTS.ai
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group (STG) reported its 2025 results: revenue was 9.036 billion Danish kroner (about $1.407 billion); EBITDA before special items was 1.791 billion Danish kroner (about $278 million); and free cash flow before acquisitions was 595 million Danish kroner (about $92.7 million). Multiple metrics declined year over year, and the company did not meet its Q3-updated guidance for revenue and free cash flow.
Mar.05 by 2FIRSTS.ai
Virginia Attorney General Backs Vape Enforcement Act Limiting Sales to FDA-Authorized or Pending Products
Virginia Attorney General Backs Vape Enforcement Act Limiting Sales to FDA-Authorized or Pending Products
Virginia Attorney General Jay Jones is backing new vape enforcement legislation that he said would do more than warn people about the dangers of vaping. The proposal would tighten rules on which products can be sold and increase enforcement aimed at keeping vapes out of the hands of young people.
Mar.24 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11